Allan D Levi1, David O Okonkwo2, Paul Park3, Arthur L Jenkins4, Shekar N Kurpad5, Ann M Parr6, Aruna Ganju7, Bizhan Aarabi8, Dong Kim9, Steven Casha10, Michael G Fehlings11, James S Harrop12, Kim D Anderson1, Allyson Gage13, Jane Hsieh13, Stephen Huhn13, Armin Curt14, Raphael Guzman15. 1. Department of Neurological Surgery and the Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida. 2. Department of Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan. 4. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin. 6. Department of Neurosurgery, University of Minnesota, Minneapolis, Minnesota. 7. Department of Neurological Surgery, Northwestern Feinberg School of Medicine, Chicago, Illinois. 8. Department of Neurosurgery, University of Maryland, College Park, Maryland. 9. Department of Neurosurgery, University of Texas Health Science Center, Austin, Texas. 10. Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 11. Division of Neurosurgery and Spinal Program, University Health Network, University of Toronto, Toronto, Ontario, Canada. 12. Department of Neurological Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 13. Stem Cells Inc., Newark, California. 14. Spinal Cord Injury Unit, Balgrist University Hospital, Zürich, Switzerland. 15. Department of Neurosurgery, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND:Human central nervous system stem cells (HuCNS-SC) are multipotent adult stem cells with successful engraftment, migration, and region-appropriate differentiation after spinal cord injury (SCI). OBJECTIVE: To present data on the surgical safety profile and feasibility of multiple intramedullary perilesional injections of HuCNS-SC after SCI. METHODS:Intramedullary free-hand (manual) transplantation of HuCNS-SC cells was performed in subjects with thoracic (n = 12) and cervical (n = 17) complete and sensory incomplete chronic traumatic SCI. RESULTS:Intramedullary stem cell transplantation needle times in the thoracic cohort (20 M HuCNS-SC) were 19:30 min and total injection time was 42:15 min. The cervical cohort I (n = 6), demonstrated that escalating doses of HuCNS-SC up to 40 M range were well tolerated. In cohort II (40 M, n = 11), the intramedullary stem cell transplantation needle times and total injection time was 26:05 ± 1:08 and 58:14 ± 4:06 min, respectively. In the first year after injection, there were 4 serious adverse events in 4 of the 12 thoracic subjects and 15 serious adverse events in 9 of the 17 cervical patients. No safety concerns were considered related to the cells or the manual intramedullary injection. Cervical magnetic resonance images demonstrated mild increased T2 signal change in 8 of 17 transplanted subjects without motor decrements or emerging neuropathic pain. All T2 signal change resolved by 6 to 12 mo post-transplant. CONCLUSION: A total cell dose of 20 M cells via 4 and up to 40 M cells via 8 perilesional intramedullary injections after thoracic and cervical SCI respectively proved safe and feasible using a manual injection technique.
RCT Entities:
BACKGROUND:Human central nervous system stem cells (HuCNS-SC) are multipotent adult stem cells with successful engraftment, migration, and region-appropriate differentiation after spinal cord injury (SCI). OBJECTIVE: To present data on the surgical safety profile and feasibility of multiple intramedullary perilesional injections of HuCNS-SC after SCI. METHODS: Intramedullary free-hand (manual) transplantation of HuCNS-SC cells was performed in subjects with thoracic (n = 12) and cervical (n = 17) complete and sensory incomplete chronic traumatic SCI. RESULTS: Intramedullary stem cell transplantation needle times in the thoracic cohort (20 M HuCNS-SC) were 19:30 min and total injection time was 42:15 min. The cervical cohort I (n = 6), demonstrated that escalating doses of HuCNS-SC up to 40 M range were well tolerated. In cohort II (40 M, n = 11), the intramedullary stem cell transplantation needle times and total injection time was 26:05 ± 1:08 and 58:14 ± 4:06 min, respectively. In the first year after injection, there were 4 serious adverse events in 4 of the 12 thoracic subjects and 15 serious adverse events in 9 of the 17 cervical patients. No safety concerns were considered related to the cells or the manual intramedullary injection. Cervical magnetic resonance images demonstrated mild increased T2 signal change in 8 of 17 transplanted subjects without motor decrements or emerging neuropathic pain. All T2 signal change resolved by 6 to 12 mo post-transplant. CONCLUSION: A total cell dose of 20 M cells via 4 and up to 40 M cells via 8 perilesional intramedullary injections after thoracic and cervical SCI respectively proved safe and feasible using a manual injection technique.
Authors: James D Guest; John D Steeves; M J Mulcahey; Linda A T Jones; Frank Rockhold; Rϋediger Rupp; John L K Kramer; Steven Kirshblum; Andrew Blight; Daniel Lammertse Journal: Spinal Cord Date: 2020-09-16 Impact factor: 2.772
Authors: Emmanouil I Damianakis; Ioannis S Benetos; Dimitrios Stergios Evangelopoulos; Aikaterini Kotroni; John Vlamis; Spyridon G Pneumaticos Journal: Cureus Date: 2022-04-28
Authors: Anneke Dixie Kakebeen; Alexander Daniel Chitsazan; Madison Corinne Williams; Lauren M Saunders; Andrea Elizabeth Wills Journal: Elife Date: 2020-04-27 Impact factor: 8.140